Outcomes
inflammation, death
DISEASE, INFLAMMATION, VIRUS, SECONDARY
We evaluated the laboratory efficacy, clinical results and titers of virus neutralizing antibodies (nAbs) against the Wuhan variant and Omicron sublineages BA.1, BA.2, BA.5. Primary endpoints included decrease of the positive SARS-CoV-2 PCR results on Day 4 and the nAbs increase after administration one hour and on Day 4 after administration in comparison with Day 0 (i.e. before mAbs administration).The secondary endpoints in the study included evaluation of lymphocyte concentration changes, measurement of markers of systemic inflammation (CRP, fibrinogen, D-dimer) on Day 4 of observation, and the outcome of the disease (discharge, hospitalization, death).